Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026)

Alnylam Pharmaceuticals has reported Finished Goods for 9 years, with the latest figure at $39.0 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 18.25% year-over-year to $39.0 million; the trailing twelve-month figure through Mar 2026 stood at $39.0 million (up 18.25% YoY), and the FY2025 full-year result was $32.3 million, up 22.34% from the prior year.
• Finished Goods for Q1 2026 stood at $39.0 million, up from $32.3 million in the prior quarter.
• The five-year high for Finished Goods was $39.0 million in Q1 2026, with the low at $10.4 million in Q1 2022.
• Historically, Finished Goods has averaged $27.1 million across 5 years, with a median of $27.7 million in 2023.
• The largest YoY upside for Finished Goods was 265.54% in 2022 against a maximum downside of 24.18% in 2022.
• Alnylam Pharmaceuticals' Finished Goods stood at $25.6 million in 2022, then decreased by 1.89% to $25.1 million in 2023, then climbed by 5.21% to $26.4 million in 2024, then climbed by 22.34% to $32.3 million in 2025, then climbed by 20.54% to $39.0 million in 2026.
• The last three Finished Goods figures came in at $39.0 million (Q1 2026), $32.3 million (Q4 2025), and $38.8 million (Q3 2025), per Business Quant data.